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Abstract 26 
Encapsulation of poorly water-soluble drugs into mesoporous materials (e.g. silica) has 27 
evolved as a favorable strategy to improve drug solubility and bioavailability. Several 28 
techniques (e.g. spray drying, solvent evaporation, microwave irradiation) have been 29 
utilized for the encapsulation of active pharmaceutical ingredients (APIs) into inorganic 30 
porous matrices. In the present work, a novel chalcone (KAZ3) with anticancer 31 
properties was successfully synthesized by Claisen-Schmidt condensation. KAZ3 was 32 
loaded into mesoporous (SBA-15 and MCM-41) and non-porous (fumed silica, FS) 33 
materials via two techniques; electrohydrodynamic atomization (EHDA) and solvent 34 
impregnation. The effect of both loading methods on the physicochemical properties of 35 
the particles (e.g. size, charge, entrapment efficiency, crystallinity, dissolution and 36 
permeability) was investigated. Results indicated that EHDA technique can load the 37 
active in a complete amorphous form within the pores of the silica particles. In contrast, 38 
reduced crystallinity (~79%) was obtained for the solvent impregnated formulations. 39 
EHDA engineered formulations significantly improved drug dissolution up to 30-fold, 40 
compared to the crystalline drug. Ex vivo studies showed EHDA formulations to exhibit 41 
higher permeability across rat intestine than their solvent impregnated counterparts. 42 
Cytocompatibility studies on Caco-2 cells demonstrated moderate toxicity at high 43 
concentrations of the anticancer agent. The findings of the present study clearly show 44 
the immense potential of EHDA as a loading technique for mesoporous materials to 45 
produce poorly water-soluble API carriers of high payload at ambient conditions. 46 
Furthermore, the scale up potential in EHDA technologies indicate a viable route to 47 
enhance drug encapsulation and dissolution rate of loaded porous inorganic materials. 48 
KEYWORDS: Mesoporous silica, chalcones, electrohydrodynamic atomization, 49 
electrospraying, poor solubility, ex vivo, molecular modelling, cytocompatibility 50 
 3 
 
1. Introduction 51 
Cancer is a deleterious disease that accounts for a high annual global mortality rate. 52 
Progress in the development of novel cancer therapies is timely and rapid, however has 53 
not resulted in a satisfactory decrease in cancer related morbidity [1]. Conventional 54 
chemotherapeutic agents encounter numerous issues such as off-target cytotoxicity, 55 
poor water solubility, limited permeability and high clearance. As a result, the 56 
bioavailability of the API remains poor not achieving sufficient concentration at the 57 
tumour site [2]. Therefore, the need to develop appropriate anticancer agents and 58 
suitable drug delivery systems for efficient cancer therapy is urgent. Chalcones, either 59 
naturally occurring or their synthetic analogues, are a group of biologically active 60 
compounds with anti-inflammatory, anti-mutagenic, antipyretic, analgesic, and 61 
antioxidant activities [1,3]. Interestingly, they are emerging in anticancer drug 62 
discovery and are attracting a significant attention from drug designers [4]. They can 63 
exert cytotoxic, anti-mitotic, anti-proliferative properties via molecular alteration such 64 
as apoptosis induction, mitochondrial damage, kinases and tubulin inhibition, and 65 
angiogenesis inhibition. [1,3-6].  Chalcones possessing lower hydroxylation and higher 66 
methoxylation are more efficient in inducing apoptosis and inhibiting proliferation [6], 67 
and especially their substituted derivatives are known to minimally interact with 68 
biological molecules compared to the conventional clinically used drugs, thus inducing 69 
a lower risk of genotoxicity and mutagenicity [4]. Although these biological properties 70 
offer them an exciting prospect, their poor aqueous solubility has restricted their 71 
medical and pharmaceutical applications [7].   72 
Various strategies have been explored to enhance drug solubility [8-14] among which 73 
solid dispersions [11,13], nanosizing [15], inclusion complexes [16], spray drying [17], 74 
electrohydrodynamic atomization (EHDA) [18] and loading into mesoporous materials 75 
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[19-23]. Utilising amorphous forms of active pharmaceutical ingredients (API) has also 76 
gathered appreciable pace over the last decade due to their high dissolution rate and 77 
bioavailability [24].  78 
Mesoporous silica materials (pore size 2 - 50 nm) have been explored as targeted [2,25] 79 
responsive [26] and controlled [27,28] drug delivery systems, because of their 80 
favourable features, such as a stable ordered porous network, accessible silanol groups, 81 
high surface area as well as uniform and tuneable pore and particle size [29]. They are 82 
considered as promising API carriers which improve the dissolution rate and oral 83 
bioavailability of poorly water-soluble drugs [21,30] by drug amorphization [19]. 84 
Previous studies have utilized mesoporous silica to improve the dissolution of 85 
telmisartan [10], ibuprofen [20], fenofibrate [23], itraconazole [21], piroxicam [19], 86 
camptothecin [31] and paclitaxel [32]. Numerous studies clearly indicate that the drug 87 
loading method on mesoporous silica materials has a substantial impact on the resulting 88 
properties of the active such as on their stability, amorphous state, loading efficiency, 89 
dissolution rate and bioavailability [8,23,33]. EHDA (also termed electro-spraying) is 90 
considered a versatile and flexible technique for the preparation of polymeric nano- and 91 
micro-particulate materials with high API encapsulation efficiency and narrow particle 92 
size distribution and has been explored for a wide range of pharmaceutical and 93 
biomedical applications [9,18,34,35]. 94 
In the present work, a novel chalcone (KAZ3) with high degree of methoxylation was 95 
successfully synthesized using the Claisen-Schmidt condensation method. KAZ3 is a 96 
poorly soluble compound therefore a good candidate for assessing the dissolution 97 
enhancing effect of electrospraying technique utilizing silica matrices as the drug 98 
carrier.  KAZ3 was loaded into mesoporous (SBA-15, MCM-41) and non-porous 99 
(fumed silica) particles using the solvent impregnation and EHDA techniques. Among 100 
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different mesoporous carriers, the hexagonally ordered mesostructured SBA-15 and 101 
MCM-41 are the most investigated mesoporous materials in literature, because of the 102 
high stability of their mesostructures and their convenient method of synthesis 103 
[21,29,36].  Although both materials are made of amorphous SiO4 tetrahedra and have 104 
hexagonally arranged arrays of pores [29], they differ in pore geometry. SBA-15 105 
possesses circular pore geometry, a wider pore size (5-10 nm) and a thicker wall, 106 
compared to MCM-41 which is characterized by a hexagonal pore geometry and pores 107 
in the range of 2-5 nm [36,37].  108 
In the present study, the drug loaded mesoporous formulations were developed after 109 
process optimization (jet mapping) and were characterized in terms of particle size and 110 
morphology (scanning electron microscopy, laser diffraction), contact angle and drug 111 
crystallinity (differential scanning calorimetry, Fourier Transform Infrared 112 
Spectroscopy, Powder X-ray diffraction). The dissolution and permeability profiles of 113 
the drug loaded mesoporous formulations were assessed in vitro in phosphate buffer 114 
solution pH 7.4 (PBS) and ex vivo using the non-everted gut sac method, respectively. 115 
Cytotoxicity evaluation of the mesoporous formulations was conducted on intestinal 116 
epithelial cells (Caco-2 cells). 117 
To the best of our knowledge, this is the first thorough study on EHDA engineering for 118 
direct drug loading into mesoporous materials. The potential for enhanced drug loading, 119 
increased stability of the drug in the amorphous state, ultimately displaying improved 120 
dissolution and permeability profiles is demonstrated.   121 
 122 
 123 
 124 
 125 
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2. Materials and methods 126 
2.1 Materials 127 
3′,4′,5′-Trimethoxyacetophenone, 4-Anisaldehyde, sodium hydroxide, methanol, ethyl 128 
acetate, petroleum ether and anhydrous magnesium sulphate were purchased from Alfa 129 
Aesar (Lancashire, UK) and Fisher Scientific (Loughborough, UK). Ethanol, Acetone, 130 
Pluronic P123, tetraethylorthosilicate (TEOS 98%) ammonia (NH3 25%) and 131 
cetylmethylammonium bromide (CTAB) were supplied from Sigma-Aldrich Chemical 132 
Company (Dorset, UK). All reagents were of the analytical grade. Non-porous fumed 133 
silica AEROSIL® 130 was obtained from Evonik Industries AG. 134 
 135 
2.2 Synthesis of (E)-3-(4-methoxyphenyl)-1-(3,4,5-trimethoxyphenyl)-prop-2-en-136 
1-one (KAZ3) 137 
The Claisen-Schmidt condensation reaction (Supplementary Material [SM], scheme 138 
S1) was adopted for chalcone synthesis [38].  Briefly, sodium hydroxide solution (50 139 
% w/v, 66.7 mmoles, 5.3 mL) was added to a stirred solution of the 3′,4′,5′-140 
Trimethoxyacetophenone (0.908g, 6.67 mmoles) and 4-anisaldehyde (1.4g, 6.67 141 
mmoles) in methanol (30 mL). The resulting mixture was stirred at room temperature 142 
and sequentially monitored by TLC (ethyl acetate/petroleum ether (3:7) upon the 143 
completion of the reaction. The reaction was quenched with distilled water (30 mL) and 144 
extracted with ethyl acetate (3 x 30 mL). The combined organic extract was washed 145 
with brine (50 mL), dried with anhydrous magnesium sulphate and the solvent was 146 
removed under vacuum. The crude product was recrystallized from ethanol to afford a 147 
yellow solid of 1.96 g (89 % yield). The structure of the formed chalcone was confirmed 148 
using an array of different analytical methods including nuclear magnetic resonance 149 
 7 
 
(NMR), mass spectroscopy (MS), Fourier transform infrared spectroscopy (FTIR) and 150 
thin layer chromatography (TLC). (SM, section 1.2)  151 
 152 
2.3 Molecular simulations  153 
Molecular dynamics (MD) calculations were performed using the program Materials 154 
Studio, in order to screen whether microporous or mesoporous materials would be 155 
better carrier candidates of KAZ3 [39]. A single drug molecule was placed inside the 156 
framework of each of the two host structures (microporous zeolites and mesoporous 157 
silica).  Periodic boundary conditions were applied, and the simulations were performed 158 
at a temperature of 310K.  The universal forcefield was used with charges calculated 159 
via the QEq methodology.  Each simulation was run for a total of 4 million steps with 160 
a time-step of 1 x 10-15 s. 161 
 162 
2.4 Synthesis and characterization of mesoporous silica host. 163 
2.4.1 Synthesis of SBA-15 particles 164 
The SBA-15 mesoporous particles were prepared according to a well-established 165 
method [40], using triblock copolymer EO20PO70EO20 (Pluronic P123) as the 166 
surfactant and tetraethylorthosilicate (TEOS 98 %) as the silica source. The surfactant 167 
was initially dissolved in an acidic (HCl) aqueous solution at 35 °C, followed by the 168 
addition of TEOS under stirring at 35 °C for 2h. The mixture was transferred into an 169 
autoclave, maintained at 35 °C for 20 h (without stirring) and subsequently aged at 90 170 
°C for 24 h. The solid product was recovered by filtration without washing and air-171 
dried at 80 °C. The removal of the surfactant took place through calcination at 550 °C 172 
for 6 h with a heating rate of 1 °C /min. 173 
 174 
 175 
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2.4.2.  Synthesis of MCM-41 particles 176 
The MCM-41 particles were synthesized under basic conditions through the hydrolysis 177 
of TEOS in a water/ammonia (NH3 25 % w/w) mixture containing 178 
cetylmethylammonium bromide (CTAB) as the surfactant agent [41]. The mixture was 179 
stirred for 30 min and subsequently heat-treated at 80 °C for 96 h in an autoclave. The 180 
final product was retrieved after filtering, rinsing with cold ethanol and air-drying, 181 
followed by calcination at 550 °C for 5 h (heating rate: 2 °C/min).  Geometry and pore 182 
volume of the produced mesoporous silica were characterized using small angle X-ray 183 
scattering (SAXS) and N2 adsorption-desorption isotherms (SM, section 1.3)  184 
 185 
2.5 Drug loading methods 186 
2.5.1.  Solvent impregnation method 187 
SBA-15, MCM-41 or FS particles (6 mg/mL) were dispersed in acetone or ethanol drug 188 
solutions (2 mg/mL) using a water bath sonicator for 15 minutes. The resulting 189 
suspensions (target drug loading was set at 25 % w/w, SM, Section 2.3) were 190 
magnetically stirred overnight in screw-capped vials. An aliquot of 1 mL of the 191 
dispersion was centrifuged and drug was quantified in the supernatant with UV 192 
spectrophotometry. The cap was removed in order to allow evaporation of solvents 193 
whilst stirring to obtain KAZ3 loaded mesoporous silica particles in a solidified form. 194 
 195 
2.5.2.  Electrospraying method 196 
Identical procedures were used to prepare dispersions of mesoporous or non-porous 197 
silica in drug solutions. Five millilitres of each dispersion were loaded into a syringe 198 
which was connected to a stainless steel conductive needle using silicone tubing. A 199 
syringe pump (world precision instruments, UK) was used to control the infusion rate 200 
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(25 μL/min) of suspensions through the needle. An electric field (16 -17.5 kV) was 201 
applied to the metallic needle using a high voltage power supply (Glassman high 202 
voltage supply, UK). The deposited particles were collected for 3.5 h onto a glass 203 
substrate.  It is worth mentioning that increasing silica particle concentration of the 204 
suspension above 12 mg/mL resulted in blockage of the needle nozzle. For scaling up, 205 
the electrospraying could be performed by adopting a multiple nozzle system, a nozzle-206 
less system or by increasing the nozzle diameter. The drug content of the sprayed 207 
product was quantified with UV spectrophotometry. Accurately weighted amounts of 208 
each sample were dispersed in acetone and sonicated for 20 minutes. The suspensions 209 
were then centrifuged, and the drug content was quantified in the supernatant solutions.  210 
 211 
2.6 Drug loading efficiency 212 
The composition of the drug-loaded samples, loading methods and entrapment 213 
efficiencies using UV spectrophotometry are presented in Table 1. The entrapment 214 
efficiency (EE %) was calculated according to equation 1. 215 
𝐸𝐸% =  
𝐴𝑐𝑡𝑢𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑝𝑟𝑒𝑠𝑒𝑛𝑡 𝑖𝑛 𝑠𝑎𝑚𝑝𝑙𝑒𝑠
𝐸𝑥𝑝𝑒𝑐𝑡𝑒𝑑 𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 
 𝑥 100      [1] 216 
 217 
2.7  Jet mapping 218 
Jetting maps were established by gradually increasing both flow rate (1-100 µL/min) 219 
and applied voltages (0 - 20 kV) in order to optimize the electrospraying process. For 220 
map construction, suspensions of silica particles (MCM-41, SBA-15 and FS) in acetone 221 
and ethanol were used. The jetting behaviour was monitored using a camera (GX CAM 222 
HiCHROME-MET, GT vision, Suffolk, UK) and images of jetting modes were 223 
obtained. 224 
 225 
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2.8 Scanning electron microscopy (SEM) studies 226 
The morphology of loaded and unloaded silica particles was investigated by means of 227 
scanning electron microscopy (SEM, Carl Zeiss EVO HD-15, Oberkochen, Germany). 228 
Particles were mounted onto double adhesive layer on an aluminium stub. The samples 229 
were gold-coated using ion sputtering device (Edwards S150B, West Sussex, UK) and 230 
scanned at an accelerating voltage of 10 kV. 231 
 232 
2.9 Thermal gravimetric analysis (TGA) 233 
Thermal gravimetric analysis of pristine silica materials, physical mixtures (drug/silica) 234 
and the drug loaded samples was performed using a TGA analyzer (Perkin Elmer, 235 
Pyris). Samples (~5 mg) were placed in porcelain pans and were heated in nitrogen gas 236 
over the range 20-800 °C with a heating rate of 10 °C/min. Entrapment efficiency was 237 
calculated using equation 2. 238 
𝐸𝐸% =
%𝑊𝑡 𝑙𝑜𝑠𝑠 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑙𝑜𝑎𝑑𝑒𝑑 𝑠𝑎𝑚𝑝𝑙𝑒𝑠 𝑓𝑟𝑜𝑚( 100−800℃)− % 𝑤𝑡 𝑙𝑜𝑠𝑠 𝑜𝑓 𝑠𝑖𝑙𝑖𝑐𝑎 𝑓𝑟𝑜𝑚 (100−800℃)
𝑇ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑑𝑟𝑢𝑔 𝑐𝑜𝑛𝑡𝑒𝑛𝑡 %
      [2] 239 
 240 
2.10  Differential scanning calorimetry (DSC) 241 
The thermograms of the KAZ3, MCM-41, SBA-15, FS, physical mixtures and the drug 242 
loaded samples were obtained on a PerkinElmer differential scanning calorimeter 243 
(Shelton, USA). The samples (~5 mg) were loaded in aluminum pans and were heated 244 
from 20 - 400 °C at a rate of 10 °C/min under a nitrogen stream at a flow rate of 20 245 
mL/min. The percentage of crystallinity of the drug loaded samples was calculated 246 
using the enthalpy of melting according to equation 3 [42]:  247 
% Crystallinity =
∆𝐻𝑚
∆𝐻𝑚°
  x 100%        [3] 248 
Where ∆Hm is the melting enthalpy of the drug loaded formulations, ∆𝐻𝑚0  is the 249 
melting enthalpy of a fully crystalline reference material (100 % crystallinity); in the 250 
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current study, the physical mixture of each silica type with equivalent drug quantity 251 
was considered as the reference material.  252 
 253 
2.11  Powder X-ray diffraction (PXRD) 254 
The crystalline state of the raw materials and the drug loaded samples was investigated 255 
by PXRD analysis on a Bruker D8-Advance diffractometer (USA) using Cu Kα1 256 
radiation (λ = 1.54 Å) over the 2θ range from 8o to 35o and a step size of 0.03o.   257 
 258 
2.12  Contact angle measurements 259 
Water contact angle on drug, unloaded and drug loaded mesoporous silicas were 260 
measured using a sessile drop profile by an optical tensiometer (Theta Lite, Biolin 261 
Scientific, Sweden). A water drop of approximately 5µL of each sample was deposited 262 
using a liquid manual dispenser (Hamilton syringe with a 22 gauge needle) on a smooth 263 
homogenous surface. The images of the drop were recorded at different time intervals.  264 
The contact angles were measured on both sides of the sessile drop and the average was 265 
taken as the result. 266 
 267 
2.13  In vitro release studies 268 
Pure drug or drug-loaded formulations were suspended in 2 mL of phosphate buffer 269 
saline (PBS) solution in capped Eppendorf tubes. In vitro release studies were 270 
conducted in a shaking water bath (60 rpm) at 37 °C under sink conditions. At different 271 
time intervals, the Eppendorfs were centrifuged and 1.5 mL samples were withdrawn 272 
and replaced with the same volume of fresh PBS. The drug content in each sample was 273 
quantified with UV spectrophotometry at 350 nm. Release experiments were carried 274 
out in triplicate and averaged results were reported. 275 
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2.14  Ex vivo intestinal permeability studies 276 
Ex vivo intestinal permeation of KAZ3 (250 μg) from suspensions and the KAZ3 loaded 277 
silica particle formulations, containing equivalent amount of drug, was evaluated using 278 
the non-everted gut sac method [43]. Male Wistar rats were fasted overnight with free 279 
access to water. The animals were euthanized and the small intestine was excised by 280 
cutting from the upper end of the duodenum to the lower end of the ileum. Intestine 281 
was thoroughly washed with cold Krebs-Ringer solution using a syringe with a blunt 282 
end. The non-everted tissue was cut into 5 cm segments and tied with silk suture from 283 
the one end. After filling with 0.5 mL of either KAZ3 suspension or KAZ3 loaded 284 
particle suspensions (equivalent to 0.25 mg KAZ3) both intestinal ends were knotted, 285 
and the formed sacs were immersed in 200 mL oxygenated Krebs-Ringer solution pH 286 
7.4 at 37 oC. Aliquots of 1 mL were withdrawn at 30, 60, 90 and 120 min and 287 
replenished with an equal volume of fresh pre-warmed buffer solution. Samples were 288 
filtered through 0.22 μm membrane syringe filters and the amount of drug permeated 289 
was quantified with HPLC analysis (SM, section 1.6). Experiments were conducted in 290 
accordance with the European Community guidelines for the use of experimental 291 
animals. 292 
The amount of drug which permeated across the intestine was determined using 293 
equation 4. 294 
Apparent permeability (µg/cm2)  =  
concentration x volume
mucosal surface area 
        [4] 295 
The mucosal surface area was calculated according to equation 5, considering the 296 
intestine a cylinder. 297 
Mucosal surface area (cm2) = 𝜋 ×  𝑑𝑖𝑎𝑚𝑒𝑡𝑒𝑟 ×   intestine length   [5] 298 
 299 
 300 
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2.15  Cytocompatibility studies 301 
Caco-2 cells (colon adenocarcinoma human cell line) were cultured in Dulbecco’s 302 
modified Eagles Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 303 
and 100 U/mL penicillin, and 100 μg/mL streptomycin and maintained at 37 oC in a 304 
humidified atmosphere (95% relative humidity) containing 5% v/v CO2. In stock 305 
cultures, cells were subcultured by trypsinization in tissue culture flasks every 48 - 72 306 
hours. In the experiments described, Caco-2 cells were used at passages 40 - 45. 307 
 308 
2.16  In vitro cytotoxicity assay 309 
The cytotoxicity effect of pure KAZ3 and the drug loaded MCM-41, SBA-15 and FS 310 
materials on Caco-2 cells was evaluated by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-311 
diphenyltetrazolium bromide) colorimetric assay (Trevingen®) [44,45] in a time- and 312 
concentration-dependent manner. Caco-2 cells were seeded in 96-well plates at an 313 
initial density of 104 cells/well and were left overnight to attach. The cells were then 314 
exposed to KAZ3 at increasing concentrations (0.1 μM - 100 μM) and the drug loaded 315 
MCM-41, SBA-15 and FS carriers at two different concentrations (0.1 mg/mL and 1 316 
mg/mL) for 4 h, 24 h and 48 h. Untreated cells were considered as negative control, 317 
whereas cells treated with 1 % v/v Triton X-100 were used as positive control. After 318 
the specified time-points, 10 μL of the MTT reagent (5 mg/mL) were added in each 319 
well and the 96-well plate was incubated for a further 1 h at 37 oC in a humidified 320 
atmosphere. The medium was then replaced with 100 μL DMSO to allow dissolution 321 
of the formed formazan crystals and the absorbance of the colored, solubilized product 322 
was read at 590 nm using an ELISA microplate reader. Percent cell viability was 323 
calculated according to equation 6. 324 
Relative cell viability (%) = (ODtreated cells-ODblank)/(ODcontrol cells-ODblank) x 100.  [6] 325 
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Results are expressed as the mean value ± standard deviation (S.D.) of three 326 
independent experiments.  327 
 328 
3. Results and Discussion 329 
3.1.  KAZ3 Synthesis and characterization 330 
The chemical structure of the synthesised chalcone (KAZ3) is shown in Figure S1. The 331 
drug was synthesized to afford a decorated aromatic ring with 4-methoxyphenyl (B-332 
ring) and 3,4,5-trimethoxyphenyl (A-ring). Methoxylation of the aromatic groups 333 
intended to increase the antiproliferative activity of the drug [6]. In addition, this 334 
decoration aimed to decrease the reactivity of α, β-unsaturated carbonyl group thus 335 
decreasing their possible interactions with biological molecules and therefore the 336 
potential of adverse effects [7]. The purity of the product was determined by TLC and 337 
elemental analysis. The product was also characterized by proton & carbon-13 NMR, 338 
infrared spectroscopy and mass spectrometry (SM, Figure S2). 339 
3.2.  Molecular simulation studies 340 
The simulations were used to investigate the diffusion properties of KAZ3 inside a 341 
typical microporous zeolite (BEA) and a mesoporous material (MCM-41) in order to 342 
determine the most pertinent carrier for loading and release of KAZ3, prior to carrying 343 
out experimental studies. MCM-41 was chosen to be a model for mesoporous silica as 344 
it is difficult run MD studies for SBA-15 due to its amorphous character since the exact 345 
nature of the structure is not well-defined.  Snapshots of the position of KAZ3 during 346 
the course of the simulation show that the molecule does not diffuse through the 347 
microporous channels of the BEA structure (Figure 1A).  Although the molecule fits 348 
inside the zeolite, it is unable to travel through the structure because it is too bulky to 349 
move between the intersections in the zeolite’s channel system.  This lack of movement 350 
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is confirmed by the calculated root-mean displacement for the molecule, which shows 351 
a flat line (Figure 1C).  In contrast, the RMS displacement for the drug inside the MCM-352 
41 framework shows a steady increase during the course of the simulation (Figure 1C).  353 
KAZ3 is easily accommodated within the larger channel system of MCM-41 (Figure 354 
1B) and interacts with the –OH groups on the internal surface, but the interaction is 355 
insufficiently strong for it to be held tightly in place at the simulation temperature. As 356 
a result, the molecule moves slowly across the internal surface of MCM-41. The 357 
simulations suggest that mesoporous materials of this type may be relatively easy to 358 
load, and that some degree of controlled release will be observed experimentally.  As a 359 
result, mesoporous materials (MCM-41 and SBA-15), rather than microporous were 360 
selected for experimental investigation.  361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
 369 
 370 
 371 
 372 
 373 
A B 
 16 
 
Figure 1. Snapshots showing the location of the drug molecule in A. BEA and B. MCM 374 
framework every 40 ps during the simulation run. C. Root mean squared displacement 375 
for KAZ3 in BEA and MCM-41.  376 
 377 
3.3   Structural characterization of porous carriers 378 
X-ray diffractograms (SM, Figure S3) of both mesoporous materials (SBA-15 and 379 
MCM-41) exhibited the typical pattern of 2-D hexagonal space group (p6mm). The N2 380 
adsorption data (SI, Figure S3 and Table S1) showed that both materials depict large 381 
BET areas (700-1000 m2/g) and pore volumes (~1 cm3/g), as well as a narrow pore size 382 
distribution (PSD) with a mean pore width of 8 nm for SBA-15 and 4 nm for MCM-41. 383 
MCM-41 materials are generally characterized by a pore size of 2 to 10 nm, while SBA-384 
15 exhibit larger pores between 4.6 to 30 nm [46]. For drug delivery applications, the 385 
pore sizes usually range between 3 and 10 nm [28]. 386 
 387 
3.4.   Jetting maps 388 
Four different modes were encountered during EHDA; (i) dripping mode, (ii) unstable 389 
jetting mode, (iii) stable single jet and (iv) stable multi jet. The dripping mode is 390 
observed when a liquid fragment rises from the nozzle exit often without sufficient 391 
applied voltage, while the stable jetting is obtained when the liquid breaks into finer 392 
droplets [47]. The jetting maps for all sprayed formulations are shown in Figure 2 (A-393 
F). The jetting maps are constructed to enable the detection of a relationship between 394 
the flow rate and the applied voltage; yellow regions represent the dripping mode; green 395 
sections show stable jetting and the blue areas display unstable jetting states. The 396 
dripping mode was attained in all sprayed formulations, generally observed when low 397 
voltages were applied (0 - 10 kV). Increasing the applied voltage to >10 kV yielded 398 
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unstable jetting modes but required further increments to be balanced with flow rate (as 399 
shown in each jetting map) to ensure that stable jetting is achieved.  400 
 401 
 402 
 403 
 404 
 405 
 406 
 407 
 408 
 409 
 410 
 411 
 412 
 413 
 414 
 415 
 416 
 417 
 418 
 419 
Figure 2. Jetting images i) micro-dripping ii) unstable jetting iii) stable cone jet iv) 420 
stable multi-jet and jetting maps of A. SBA-15 in acetone B. SBA-15 in ethanol C. 421 
MCM-41 in acetone D. MCM-41 in ethanol E. FS in acetone and  F. FS in ethanol. 422 
3.5.   Particle morphology 423 
 
   
   
    
B 
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SEM images of the pristine silica particles and the loaded formulations (20 kX) are 424 
shown in SM, Figure S5. Selected formulations are shown in Figure 3 at a higher 425 
magnification (40 kX) to examine the impact of drug loading on particle surface. Drug-426 
loaded formulations prepared using solvent impregnation show rough topographical 427 
features as a result of dispersed active crystal formation on their surface (Figure 3D).  428 
 429 
 430 
 431 
 432 
 433 
 434 
 435 
 436 
 437 
 438 
 439 
 440 
 441 
 442 
 443 
Figure 3. Scanning electron microscope images of A. and B. SBA-15 at 5 kX and 40 444 
kX magnification, respectively. C. and D. SBA-Eth-SIM at 5 kX and 40 kX 445 
magnification, respectively. E. and F. SBA-Eth-SP at 5 kX and 40 kX magnification, 446 
respectively. SBA: SBA-15, Eth: Ethanol, SIM: solvent impregnation method and SP:  447 
electrospraying method. 448 
A B 
C D 
E F 
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In contrast, electrosprayed particles (Figure 3F) preserve particle surface morphology 449 
exhibiting smooth surfaces with little to none drug crystals present on the particle 450 
surface. This observation indicates that most drug is encapsulated within the pores of 451 
mesoporous silica. Lower magnification analysis (5 kX) revealed an aggregation 452 
tendency post drug loading. Solvent impregnated particles showed a greater tendency 453 
to aggregate during the loading process to form coarse clusters (Figure 3C), attributed 454 
to the cohesive properties of surface deposited drug crystals [8]. However, particles 455 
engineered using electrospraying appear more scattered and the presence of fused fiber-456 
like structures is reduced (Figure 3E). During the electrospraying process mesoporous 457 
silica particles are atomized into smaller droplets favouring the disaggregation of the 458 
longer chained agglomerates into individual rod like structures.  459 
 460 
3.6.  Drug content and entrapment efficiency (EE%) 461 
3.6.1 Determination of EE % using UV spectrophotometry 462 
The drug loading efficiencies of all formulations are listed in Table 1. The results reveal 463 
that the loading method affects the loading efficiency of mesoporous silica particles. 464 
The loading efficiency of electrosprayed mesoporous silica was higher compared to 465 
those prepared using the solvent impregnation technique, exceeding 90.5 %. On the 466 
contrary, formulations prepared using the solvent impregnation technique showed 467 
loading efficiencies up to 35.6 %. The significant improvement in loading efficiency 468 
using EHDA is attributed to the rapid evaporation of sprayed solvent droplets, due to 469 
instabilities and bending motions which force the drug to be infiltrated inside the silica 470 
pores. Furthermore, droplets arising from the atomisation process naturally increase the 471 
surface area for drying. The choice of organic solvent also affects the loading 472 
efficiency. The loading efficiency of SBA-AC-SIM particles was higher (35.65 %) 473 
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compared to that of SBA-Eth-SIM (18.29 %), accounting for the lower polarity of 474 
acetone compared to ethanol. The more polar solvent (ethanol) favours the 475 
accommodation of large quantities of KAZ3 in solution, thus lowering the amount of 476 
drug adsorbed into pores [48]. The use of acetone for electrospraying mesoporous silica 477 
particles resulted in loading efficiencies of up to ~100 % with high intra-batch 478 
variability. In these cases, heterogeneous dispersions of the drug within the silica matrix 479 
were obtained, because of sedimentation of silica particles in the drug solution during 480 
the electrospraying process.  481 
The pronounced effect of acetone on particle instability is further corroborated by ζ-482 
potential measurements (SM, Table S4). The ζ-potential values of mesoporous silica 483 
particles in acetone were -9.75 mV for SBA-15 and -4.45 mV for MCM-41. On the 484 
contrary, the absolute value of ζ-potential data obtained for ethanol based mesoporous 485 
silica dispersions was higher than 30 mV for both types indicating greater stability [49]. 486 
The effect of medium viscosity is equally important for dispersion stability. The low 487 
viscosity of acetone (0.39 cP) resulted in accelerated sedimentation of silica in the 488 
organic solvent. On the contrary, the greater viscosity of ethanol (1.1 cP) led to a more 489 
stable suspension. It is well accepted that the type of silica substrate greatly influences 490 
the loading efficiency of the drug. For the solvent impregnation method, mesoporous 491 
SBA-15 displayed higher loading efficiency than MCM-41, due to the larger pore size 492 
of SBA-15 compared to MCM-41. With regard to electrosprayed formulations, both 493 
types achieved similar drug encapsulation values (EE ≥ 90.58%).  Reduced drug 494 
loading values were obtained using non-porous FS. The drug content in nonporous FS 495 
formulations is attributed to surface drug adsorption, originating from interactions 496 
between the active compound and the surface silanol groups. 497 
 498 
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3.6.2 Determination of EE % using TGA 499 
The thermogravimetric behaviour of silica particles before and after drug loading is 500 
shown in SM (Figure S8). The drug content of the silica formulations was determined 501 
following correction of the TG curve from water content by using the weight loss at 502 
temperature range 100 - 800 ◦C, as by this stage, all drug content had decomposed. EE’s 503 
are listed in Table 1.  The EE of solvent impregnated samples were found to be higher 504 
than those calculated spectrophotometrically. TGA was performed on dried samples, 505 
which accounts for drug deposits on the surface following complete solvent 506 
evaporation. However, calculated EE for electrosprayed samples were similar to the 507 
ones calculated using spectrophotometry.  As shown in Table 1, the electrosprayed 508 
mesoporous formulations exhibited higher EE compared to those loaded using the 509 
solvent impregnation method. 510 
 511 
3.7.  XRD and DSC studies 512 
XRD and DSC were used to characterize the physical state of the drug in the silica 513 
formulations. XRD patterns of drug loaded formulations are demonstrated in Figure 4 514 
(A, B & C).  No diffraction peaks were detected in any of the electrosprayed 515 
mesoporous formulations as compared to the pure crystalline drug or to the 516 
corresponding physical mixture, indicating the presence of the drug in the amorphous 517 
state in the mesopores of the silica, because of the fast solvent evaporation of the EHDA 518 
technique. The X-ray diffraction patterns of the solvent impregnated formulations 519 
showed characteristic peaks of the drug in the crystalline state, but with lower 520 
intensities for the acetone impregnated formulations and sharper peaks for the ethanol 521 
impregnated samples, suggesting the presence of drug precipitates on the surface of the 522 
silica particles, due to the slow solvent evaporation during this technique. XRD results  523 
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correlate well with the data obtained from DSC studies [Figure 4 (D, E & F)]. The 524 
percentage of drug crystallinity in each formulation was determined using the drug’s 525 
melting enthalpies (SI, Table S5). The thermogram of the pure crystalline drug exhibits 526 
a sharp endothermic melting peak at 101 °C. The thermograms of the physical mixtures 527 
show a sharp peak at 98 °C. All solvent impregnated formulations showed a broadened 528 
endothermic peak at 116 °C for SBA-15 formulations and at 108 °C for MCM-41 529 
samples. The broadening and shift of the melting peaks suggests a reduction in drug 530 
crystallinity, indicating partial amorphization [50]. 531 
The percentage of drug crystallinity in the solvent impregnated formulations ranged 532 
between 33.18 % and 79.85 % and a higher crystallinity was detected for the ethanol 533 
than the acetone impregnated formulations. No endothermic peaks were detected in the 534 
thermograms of the electrosprayed formulations using ethanol (SBA-Eth-SP and 535 
MCM-Eth-SP), indicating drug entrapment in the silica in the amorphous state [51].  536 
The absence of drug’s melting peak in the thermograms of drug loaded mesoporous 537 
particles has been previously reported in several studies [8,42,51]. However, 538 
electrosprayed formulations using acetone (for SBA-AC-SP and MCM-AC-SP) 539 
showed a small melting peak at approximately 95 °C and drug crystallinity was 540 
calculated to be 12.96 % and 14.82 %, respectively. This is justified by the 541 
heterogeneous dispersion of the drug within silica, leading to crystallization of a small 542 
quantity of the drug molecules. The underestimated crystallinity when using XRD is 543 
most likely related to reduced diffraction intensity upon nano- sizing [18].  544 
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Table 1. Quantification of KAZ3 encapsulation efficiency (EE %) of the different formulations calculated by UV spectrophotometry and TGA.
Formulation 
 
MS type 
Loading 
Method 
Solvent EE (%)-UV 
 
EE (%)-TGA 
 
Silica wt. loss 
(%) 
(100 ◦C-800 ◦C ) 
 
Formulation wt. 
loss (%) 
(100 ◦C-800 ◦C) 
KAZ3 
content (%) 
EE (%) 
SBA-AC-SIM SBA-15 
Solvent 
impregnation 
Acetone 35.65 ± 3.25 8.23 25.7 17.47 69.88 
SBA-Eth-SIM SBA-15 
Solvent 
impregnation 
Ethanol 18.29 ± 0.86 8.23 24.29 16.06 64.25 
SBA-AC-SP SBA-15 EHDA Acetone 114.53 ± 5.25 8.23 41.29 33.06 132.26 
SBA-Eth-SP SBA-15 EHDA Ethanol 91.79 ± 0.42 8.23 34.75 26.52 106.10 
MCM-AC-SIM MCM-41 
Solvent 
impregnation 
Acetone 28.53 ± 0.73 14.8 29.33 14.53 58.13 
MCM-Eth-SIM MCM-41 
Solvent 
impregnation 
Ethanol 15.28 ± 10.28 14.8 29.91 15.11 60.45 
MCM-AC-SP MCM-41 EHDA Acetone 105.89 ± 5.05 14.8 41.15 26.35 105.41 
MCM-Eth-SP MCM-41 EHDA Ethanol 90.58 ± 0.72 14.8 32.3 17.50 70.0 
FS-AC-SIM Fumed silica 
Solvent 
impregnation 
Acetone 13.14 ± 2.95 8.16 27.34 19.18 76.72 
FS-Eth-SIM 
 
Fumed silica 
Solvent 
impregnation 
Ethanol 9.48 ± 0.38 8.16 29.24 21.24 84.98 
FS-AC-SP Fumed silica EHDA Acetone 115.18 ± 7.68 8.16 36.72 28.72 114.89 
FS-Eth-SP Fumed silica EHDA Ethanol 65.35 ± 0.37 8.16 29.42 21.42 85.71 
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3.8.  Contact angle goniometry studies 545 
Contact angle is a macroscopic parameter which is often used to determine the 546 
interaction between liquid droplets (mostly water) and solid surfaces [52]. As presented 547 
in Figure 5, raw SBA-15, MCM-41 and FS showed very low contact angle values 548 
(12.6◦, 11.5◦, 16.8◦, respectively). The water droplet spread promptly all over solid 549 
particulate surfaces resulting in 0◦ contact angle within 2 sec. This result can be 550 
explained by the strong hydrophilicity of silica surfaces due to their abundant hydroxyl 551 
surface groups that are able to form hydrogen bonds with water molecules. Another 552 
reason is capillary action (wicking) of water through silica substrate due to the presence 553 
of nano-sized pores [53]. To determine the wettability of the drug, KAZ3 was sprayed 554 
using ethanol or acetone and the contact angle was measured. In both cases, the contact 555 
angle was high (> 90◦), highlighting the high hydrophobicity of the drug irrespective of 556 
the solvent used. To further evaluate the presence of drug on or within particles, the 557 
contact angle of all formulations was measured. As shown in Figure 5, the contact angle 558 
of all solvent impregnated formulations is similar to pristine mesoporous silica, 559 
indicating that mesoporous silica preserves its hydrophilicity, since the abundant free 560 
hydroxyl groups do not decrease with this technique. Also, contact angle values might 561 
be low because of the crystalline\semi crystalline nature of the surface adsorbed active 562 
[52].  In contrast, the contact angle of atomized formulations was prominently higher 563 
than raw silica and solvent impregnated formulations with values ranging from 90o to 564 
103o. This is attributed to the decrease of the free hydroxyl groups, possibly due to the 565 
interactions developed with the drug molecules, therefore decreasing hydrogen bonding 566 
with water. In addition, the wicking effect is also reduced as pores are partially blocked 567 
with drug. However, a reduction in contact angle over time was observed and varied 568 
depending on atomized formulations.569 
 25 
 
 570 
 571 
 572 
 573 
 574 
 575 
 576 
 577 
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 579 
Figure 4.  A., B., C. XRD patterns and D., E., F. DSC thermograms of pristine silica materials and drug loaded formulations.  SBA: SBA-15, 580 
MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent impregnation method and SP:  electrospraying method.581 
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For example, the contact angle of SBA-Eth-SP was 90◦ at 0 seconds and attained its 582 
lowest value (4.3◦) within 10 seconds. This reflects that drug dissolution occurs once 583 
water molecules penetrate through the pores. The respective contact angle values for 584 
SBA-AC-SP was 103◦ and reached 0◦ after 1 h. This is attributed to the higher loading 585 
efficiency of SBA-AC-SP than SBA-Eth-SP. Similar findings were obtained with 586 
MCM-41 based atomized formulations. With regard to non-porous atomized 587 
formulations (FS-Eth-SP and FS-AC-SP), values of 104◦ and 95◦ were obtained at 0 sec, 588 
respectively. However, their contact angle took a longer time to decrease than atomized 589 
mesoporous formulations (Figure 5), due to the lower dissolution rate of the adsorbed 590 
drug in formulations.   591 
In particular, contact angle studies revealed that the ethanol sprayed formulations were 592 
more hydrophilic compared to their acetone congeners. It is anticipated by extrapolation 593 
to the in vivo situation that the clearance of hydrophobic formulations would be slower; 594 
the latter, however, provides drug released amounts over extended periods of time that 595 
would be beneficial to the cellular absorption process. Complementary, it should be 596 
emphasized that hydrophobicity is a crucial factor contributing to cellular membrane 597 
permeability, since molecules are facilitated to move through the lipophilic structures. 598 
To this end, the bioaccumulation of the electrosprayed formulations is expected to be 599 
positively influenced by their hydrophobic nature, thus leading to increased permeable 600 
drug concentrations and enhanced bioavailability, especially for poorly soluble drugs.    601 
 602 
 603 
 604 
 605 
 606 
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Figure 5. Plots of θο values versus time for A. SBA-15, B. MCM-41 and C. FS before 628 
and after drug loading and D. digital images captured at different time intervals. Where 629 
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SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: 630 
solvent impregnation method and SP:  electrospraying method. 631 
 632 
3.9.  In vitro release studies  633 
In vitro release profiles of KAZ3 from all formulations are presented in Figure 6. Drug 634 
release from the loaded mesoporous silica particles showed a bi-phasic pattern with an 635 
initial burst release followed by a subsequent plateau. The dissolution rate of the drug 636 
from the atomized drug loaded mesoporous silica particles was prominently higher than 637 
from the formulations prepared using solvent impregnation (t-test, p<0.05), reaching a 638 
total of 19 % to 37.5 % drug release within 1 hr. On the other hand, solvent impregnated 639 
formulations only achieved a total of 4 % to 17 % drug release at the same time course. 640 
After 24 h electrosprayed formulations released between 41 % to 72 % of their drug 641 
content, while formulations loaded using the solvent impregnation method released 642 
between 10 % to 38 % of their total drug content. Conversely, pure crystalline drug and 643 
formulations based on FS achieved a total of 2 % and 6 % to 19 % of drug release, 644 
respectively after 24 h. This indicates that incorporation of drug within mesopores has 645 
a pronounced effect on solubility enhancement.  646 
Drug dissolution showed a 35-fold enhancement using EHDA compared to the raw 647 
crystalline drug. Solvent impregnated formulations with high crystallinity (33.2 % - 648 
79.9 %) exhibited a lower dissolution rate when compared to electrosprayed 649 
formulations. This significant enhancement in drug’s dissolution properties by 650 
electrospraying is not only attributed to KAZ3 amorphization, but also to the lower 651 
particle size of the electrosprayed formulations. By decreasing silica particle size, the 652 
diffusion distance of the drug is reduced, thus improving its release rate [8]. In contrast, 653 
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the presence of solvent impregnated silica particles yielded aggregates which partially 654 
block pores, increasing the drug diffusion distance to the dissolution media.  655 
Although larger pores result to greater dissolution rates, no significant differences were 656 
observed between the dissolution profiles of SBA-15 and MCM-41-based formulations. 657 
This observation may be a result of the lower particle size of atomized MCM-41 than 658 
atomized SBA-15, which may have compensated for the reduced pore size [8].  659 
However, a significant difference was observed between the dissolution rates of 660 
mesoporous silica-based formulations and non-porous particulates. Nonporous 661 
formulations released between 6.6 % to 18.7 % of their drug content by the end of the 662 
experiment. This demonstrates that incorporation of drug in nano-sized pores clearly 663 
improves dissolution more than interactions with surface silanol groups. 664 
 665 
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Figure 6.  In vitro release profiles of pure KAZ3 and KAZ3 loaded silica particles A. 678 
SBA-15, B. MCM-41 and C. FS using different solvents and loading methods (n=3). 679 
SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: 680 
solvent impregnation method and SP:  electrospraying method. 681 
 682 
3.10. Release kinetics 683 
The diffusion release kinetics in porous carriers is well illustrated using Higuchi and 684 
Korsmeyer-Peppas kinetic models [54-60]. The data obtained from the in vitro release 685 
studies were fitted to Higuchi [61] and Korsmeyer-Peppas [62] kinetic models (SM, 686 
Figure S9). A curve fitting analysis was performed to determine the release kinetic 687 
parameters (SM, Table S6).  688 
Applying the Higuchi model (SM, Figure S9 A, B & C) all formulations demonstrated 689 
two-step release kinetics with high R2 values for both stages. The R2 values were ≥ 0.96 690 
for the mesoporous silica-based formulations and ≤ 0.96 for the non-porous 691 
formulations. This high correlation coefficient suggests that the mechanism of release 692 
for KAZ3 through these systems is Fickian diffusion. However, the occurrence of a 693 
two-step release mechanism is possibly due to alterations to silica’s dissolution rate 694 
over time [55]. Similar two-step release kinetics for mesoporous materials for the 695 
Higuchi model have been previously reported in the literature [55-58]. The greatest KH 696 
value was attained for the electrosprayed mesoporous silica-based formulations 697 
indicating a better drug release compared to other systems. However, the release rate 698 
constant varied, depending on the silica type and the solvent used for the atomization 699 
process (SM, Table S6). 700 
The first 60 % of the in vitro release data were fitted to Korsmeyer-Peppas as shown in 701 
SM Figure S9 D, E & F. The obtained kinetic parameters (R2 and n: diffusion or release 702 
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exponent that characterizes the release mechanism of the drug) are presented in SM, 703 
Table S6. The plots of all formulations showed a linear fit to Korsmeyer-Peppas model 704 
(R2: 0.91 - 0.99). The n values of ethanol atomized formulations (MCM-Eth-SP and 705 
SBA-Eth-SP) were approximately 0.43, indicative of Fickian diffusion mechanism. 706 
However, the n values of the other formulations ranged between 0.25 to 0.35. This 707 
deviation could be attributed to the wide particle size distribution [62], resulting to 708 
fluctuations in diffusion times. The broader the size distribution [represented by span 709 
value (SM, Table S3)] the lower the n value. It is noteworthy that some studies have 710 
referred to the instance n < 0.43 as quasi-Fickian diffusion [63,64].  711 
 712 
 3.11 Ex vivo intestinal permeability studies 713 
Cumulative permeation profiles of KAZ3 dispersion and KAZ3 after loading in 714 
different silica substrates (SBA-15, MCM-41, FS) utilizing different loading techniques 715 
(electrospraying and solvent impregnation) were determined by using the non-everted 716 
intestinal sac method. Results indicated that KAZ3 in suspension form demonstrated 717 
poor permeability across the intestinal membrane, owing to its low solubility in the 718 
mucosal compartment. Similar permeability profiles were obtained for all formulations 719 
prepared via the solvent impregnation method, as well (Figure 7). On the contrary, a 720 
substantial permeation enhancement of the drug was observed for all formulations 721 
prepared via the electrospraying method. Such significant enhancement in KAZ3 could 722 
be related to the drug solubilizing effect of the electrospraying method, as already 723 
demonstrated in the in vitro release studies. The increment in the permeation enhancing 724 
effect followed the order: MCM-41 > SBA-15 > FS, being in close agreement with the 725 
in vitro KAZ3 release profiles.  726 
 32 
 
All electrosprayed mesoporous formulations reported statistically significant higher Jss 727 
and Papp values (p < 0.05), compared to both KAZ3 suspension and formulations 728 
prepared via the solvent impregnation method, as shown in Table 2. MCM-Eth-SP 729 
formulation showed the highest Papp achieving a 9.45-fold increase relative to the drug 730 
suspension. Similarly to the present study, it has been previously demonstrated that the 731 
adoption of various formulation approaches that result to improved drug solubility and 732 
dissolution rates can further contribute to improved intestinal permeability over plain 733 
drug suspensions [65,66].  734 
 735 
Table 2. Apparent permeability (Papp) and steady state flux (Jss) values of KAZ3 from 736 
different formulations using the non-everted intestinal sac method (n=3-5).  737 
Sample Jss (ng/min/cm2) Papp·10-7 (cm/s) Enhancement 
Ratio 
KAZ3 suspension 0.22 ± 0.02 8.88 ± 0.8 1 
SBA-Eth-SIM 0.21 ± 0.07 8.32 ± 2.8 0.9 
SBA-Eth-SP 0.63 ± 0.03 25.30 ± 1.2 2.8 
MCM-Eth-SIM 0.09 ± 0.01 3.60 ± 0.4 0.4 
MCM-Eth-SP 2.10 ± 0.02 84.0 ± 0.8 9.45 
FS-Eth-SIM 0.31 ± 0.01 12.5 ± 0.40 1.4 
FS-Eth-SP 0.83 ± 0.01 33.2 ± 0.39 3.7 
 738 
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 757 
Figure 7. Ex vivo permeation profiles of plain drug and drug loaded in A. SBA-15, B. 758 
MCM-41 and C. FS particles using the non-everted sac method in Krebs-Ringer 759 
solution at 37 oC (n=3-5). SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: 760 
Ethanol, AC: acetone, SIM: solvent impregnation method and SP:  electrospraying 761 
method. 762 
 763 
3.12 Cytocompatibility studies 764 
The IC50 of KAZ3 was calculated to be 6.905 μM (Figure 8A). The suitability of ordered 765 
mesoporous silica MCM and SBA for oral drug formulations has been previously 766 
thoroughly assessed on Caco-2 cells [67]. A moderate effect on cell viability was 767 
observed for most concentrations and incubation times evaluated, while particle size 768 
and shape were also found to partly contribute to cytotoxicity. In the present study, the 769 
cytotoxic effect of the drug loaded MCM, SBA and FS particles was evaluated at the 770 
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concentrations of 0.1 mg/mL and 1 mg/mL on Caco-2 cells after 4 h, 24 h and 48 h of 771 
cell exposure to the dispersions (Figure 8 B, C & D).  772 
 773 
 774 
 775 
 776 
 777 
 778 
 779 
 780 
 781 
 782 
 783 
 784 
 785 
Figure 8. A. Assessment of cell viability of Caco-2 cells exposed to KAZ3 (n=3). The 786 
cellular viability of Caco-2 cell cultures without treatment (negative control), after 787 
treatment with 1 % Triton X-100 (positive control) and after incubation with 0.1 mg/mL 788 
and 1 mg/mL of KAZ3-loaded MCM-41, SBA-15 and FS materials, for B. 4 h, C. 24 h 789 
and D. 48h was assessed by MTT assay (n=3). Eth: Ethanol, AC: acetone, SIM: solvent 790 
impregnation method and SP:  electrospraying method. 791 
 792 
No significant effect on cell viability (> 80 %) was observed after 4 h of incubation for 793 
most formulations at both concentrations tested. On the contrary, a higher cytotoxic 794 
effect was induced after 24 h and 48 h of cell exposure to the tested formulations, with 795 
A 
B 
C D 
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the effect being more pronounced (< 60 %) at the concentration of 1 mg/mL. The 796 
cellular morphology of Caco-2 cells exposed to KAZ3 for either 24 h or 48 h was altered 797 
at concentrations ≥ 1 μM (SM, Figure S10), a fact coinciding with the capacity of this 798 
agent to affect cell proliferation of Caco-2 cells (Figure 8 A). The capacity of KAZ3-799 
loaded MCM, SBA and FS formulations to cause cytotoxicity and affect the 800 
proliferation of Caco-2 cells exposed for 48 h at 0.1 mg/mL and 1 mg/mL is also 801 
indicated by assessing the cellular morphology (SM, Figure S11). The latter, coincides 802 
with the effect of these formulations to decrease the viability of Caco-2 cell cultures, as 803 
seen in Figure 8 D. 804 
  805 
Conclusions  806 
To obtain a comprehensive overview of the potentiality of electrospraying as a 807 
successful strategy to improve the solubility of poorly soluble compounds an in-depth 808 
study was conducted utilizing mesoporous (SBA-15, MCM-41) and non-porous (fumed 809 
silica) silica materials as the drug carriers of a sparingly water-soluble anticancer agent; 810 
a novel chalcone (KAZ3). Two different approaches were utilized to encapsulate the 811 
anticancer agent to the particles namely; electrospraying and solvent impregnation 812 
method whereas an array of analytical methods was employed to characterize the empty 813 
and drug loaded carriers. The electrosprayed mesoporous formulations demonstrated 814 
uniform particle size, high drug loading efficiencies with the drug encapsulated in an 815 
amorphous state, while at the same time a significant enhancement in drug dissolution 816 
up to 30-fold and drug intestinal permeability up to 9.45-fold was observed, compared 817 
to the pure crystalline drug, mainly due to drug amorphization on the silica carriers. 818 
Contact angle goniometry studies offered insights on the wettability properties of the 819 
mesoporous carriers further corroborating the in vitro and ex vivo data, whereas 820 
 36 
 
molecular dynamics offered a unique insight into the interactions between the drug and 821 
the framework and could prove to be a valuable tool in screening drug-mesoporous 822 
combinations for further experimental investigation. Importantly, the mesoporous 823 
loaded material exhibited moderate toxicity as observed by the kinetics of cell 824 
proliferation and the assessment of cell viability in Caco-2 cell cultures. Overall, the 825 
findings of the present study underlie the potential of electrosprayed silica hybrids for 826 
further research for in vivo biomedical applications. 827 
 828 
Acknowledgement 829 
The authors would like to gratefully acknowledge the Egyptian Culture Centre and the 830 
Educational Bureau in London for funding the research. The authors would also like to 831 
thank the EPSRC (EPSRC EHDA Network) for their support. 832 
 833 
Declaration of interest 834 
None 835 
 836 
 837 
 838 
 839 
 840 
 841 
 842 
 843 
 844 
 845 
 37 
 
References 846 
[1] M. Pilatova, L. Varinska, P. Perjesi, M. Sarissky, L. Mirossay, P. Solar, A. Ostro, J. 847 
Mojzis, In vitro antiproliferative and antiangiogenic effects of synthetic chalcone 848 
analogues, Toxicol in Vitro. 24 (2010) 1347-1355. 849 
[2] M. Shahbazi, B. Herranz, H.A. Santos, Nanostructured porous Si-based 850 
nanoparticles for targeted drug delivery, Biomatter. 2 (2012) 296-312. 851 
[3] S. Won, C. Liu, L. Tsao, J. Weng, H. Ko, J. Wang, C. Lin, Synthetic chalcones as 852 
potential anti-inflammatory and cancer chemopreventive agents, Eur. J. Med. Chem. 40 853 
(2005) 103-112. 854 
[4] M. Das, K. Manna, Chalcone scaffold in anticancer armamentarium: a molecular 855 
insight, Journal of toxicology. 2016 (2016). 856 
[5] R. De Vincenzo, C. Ferlini, M. Distefano, C. Gaggini, A. Riva, E. Bombardelli, P. 857 
Morazzoni, P. Valenti, F. Belluti, F.O. Ranelletti, In vitro evaluation of newly 858 
developed chalcone analogues in human cancer cells, Cancer Chemother. Pharmacol. 859 
46 (2000) 305-312. 860 
[6] C. Echeverria, J.F. Santibañez, O. Donoso-Tauda, C.A. Escobar, R. Ramirez-Tagle, 861 
Structural antitumoral activity relationships of synthetic chalcones, Int. J. Mol. Sci. 10 862 
(2009) 221-231. 863 
[7] M.N. Gomes, E.N. Muratov, M. Pereira, J.C. Peixoto, L.P. Rosseto, P.V. Cravo, 864 
C.H. Andrade, B.J. Neves, Chalcone Derivatives: Promising Starting Points for Drug 865 
Design, Molecules. 22 (2017) 1210. 866 
[8] S. Hong, S. Shen, D.C.T. Tan, W.K. Ng, X. Liu, L.S. Chia, A.W. Irwan, R. Tan, 867 
S.A. Nowak, K. Marsh, High drug load, stable, manufacturable and bioavailable 868 
fenofibrate formulations in mesoporous silica: a comparison of spray drying versus 869 
solvent impregnation methods, Drug Deliv. 23 (2016) 316-327. 870 
 38 
 
[9] J. Xie, J. Jiang, P. Davoodi, M.P. Srinivasan, C. Wang, Electrohydrodynamic 871 
atomization: A two-decade effort to produce and process micro-/nanoparticulate 872 
materials, Chem. Eng. Sci. 125 (2015) 32-57. 873 
[10] Y. Zhang, J. Wang, X. Bai, T. Jiang, Q. Zhang, S. Wang, Mesoporous silica 874 
nanoparticles for increasing the oral bioavailability and permeation of poorly water 875 
soluble drugs, Mol. Pharm. 9 (2012) 505-513. 876 
[11] C. Leuner, J. Dressman, Improving drug solubility for oral delivery using solid 877 
dispersions, Eur. J. Pharm. Biopharm. 50 (2000) 47-60. 878 
[12] R. Mellaerts, J.A. Jammaer, M. Van Speybroeck, H. Chen, J.V. Humbeeck, P. 879 
Augustijns, G. Van den Mooter, J.A. Martens, Physical state of poorly water soluble 880 
therapeutic molecules loaded into SBA-15 ordered mesoporous silica carriers: a case 881 
study with itraconazole and ibuprofen, Langmuir. 24 (2008) 8651-8659. 882 
[13] T. Vasconcelos, B. Sarmento, P. Costa, Solid dispersions as strategy to improve 883 
oral bioavailability of poor water-soluble drugs, Drug Discov. Today. 12 (2007) 1068-884 
1075. 885 
[14] A. Fahr, X. Liu, Drug delivery strategies for poorly water-soluble drugs, Expert 886 
opinion on drug delivery. 4 (2007) 403-416. 887 
[15] E. Merisko-Liversidge, G.G. Liversidge, Nanosizing for oral and parenteral drug 888 
delivery: A perspective on formulating poorly-water soluble compounds using wet 889 
media milling technology, Adv. Drug Deliv. Rev. 63 (2011) 427-440. 890 
[16] A. Figueiras, R.A. Carvalho, L. Ribeiro, J.J. Torres-Labandeira, F.J.B. Veiga, 891 
Solid-state characterization and dissolution profiles of the inclusion complexes of 892 
omeprazole with native and chemically modified β-cyclodextrin, Eur. J. Pharm. 893 
Biopharm. 67 (2007) 531-539. 894 
 39 
 
[17] A. Paudel, Z.A. Worku, J. Meeus, S. Guns, G. Van den Mooter, Manufacturing of 895 
solid dispersions of poorly water-soluble drugs by spray drying: Formulation and 896 
process considerations, Int. J. Pharm. 453 (2013) 253-284. 897 
[18] S. Zhang, K. Kawakami, M. Yamamoto, Y. Masaoka, M. Kataoka, S. Yamashita, 898 
S. Sakuma, Coaxial electrospray formulations for improving oral absorption of a poorly 899 
water-soluble drug, Mol. Pharm. 8 (2011) 807-813. 900 
[19] V. Ambrogi, L. Perioli, F. Marmottini, S. Giovagnoli, M. Esposito, C. Rossi, 901 
Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous 902 
silicate, Eur. J. Pharm. Sci. 32 (2007) 216-222. 903 
[20] T. Heikkilä, J. Salonen, J. Tuura, N. Kumar, T. Salmi, D.Y. Murzin, M. Hamdy, 904 
G. Mul, L. Laitinen, A. Kaukonen, Evaluation of mesoporous TCPSi, MCM-41, SBA-905 
15, and TUD-1 materials as API carriers for oral drug delivery, Drug Deliv. 14 (2007) 906 
337-347. 907 
[21] R. Mellaerts, R. Mols, J.A.G. Jammaer, C.A. Aerts, P. Annaert, J. Van Humbeeck, 908 
G. Van den Mooter, P. Augustijns, J.A. Martens, Increasing the oral bioavailability of 909 
the poorly water-soluble drug itraconazole with ordered mesoporous silica, Eur J Pharm 910 
Biopharm. 69 (2008) 223-230. 911 
[22] M.J.K. Thomas, I. Slipper, A. Walunj, A. Jain, M.E. Favretto, P. Kallinteri, D. 912 
Douroumis, Inclusion of poorly soluble drugs in highly ordered mesoporous silica 913 
nanoparticles, Int. J. Pharm. 387 (2010) 272-277. 914 
[23] R.J. Ahern, J.P. Hanrahan, J.M. Tobin, K.B. Ryan, A.M. Crean, Comparison of 915 
fenofibrate–mesoporous silica drug-loading processes for enhanced drug delivery, Eur. 916 
J. Pharm. Sci. 50 (2013) 400-409. 917 
 40 
 
[24] P. Gao, Amorphous pharmaceutical solids: characterization, stabilization, and 918 
development of marketable formulations of poorly soluble drugs with improved oral 919 
absorption, Mol. Pharm. 5 (2008) 903-904. 920 
[25] J.M. Rosenholm, C. Sahlgren, M. Lindén, Towards multifunctional, targeted drug 921 
delivery systems using mesoporous silica nanoparticles–opportunities & challenges, 922 
Nanoscale. 2 (2010) 1870-1883. 923 
[26] C. Lee, S. Cheng, I. Huang, J.S. Souris, C. Yang, C. Mou, L. Lo, Intracellular pH‐924 
responsive mesoporous silica nanoparticles for the controlled release of anticancer 925 
chemotherapeutics, Angewandte Chemie. 122 (2010) 8390-8395. 926 
[27] S. Song, K. Hidajat, S. Kawi, Functionalized SBA-15 materials as carriers for 927 
controlled drug delivery: influence of surface properties on matrix-drug interactions, 928 
Langmuir. 21 (2005) 9568-9575. 929 
[28] P. Horcajada, A. Ramila, J. Perez-Pariente, M. Vallet-Regı, Influence of pore size 930 
of MCM-41 matrices on drug delivery rate, Microporous Mesoporous Mater. 68 (2004) 931 
105-109. 932 
[29] E. Sayed, R. Haj-Ahmad, K. Ruparelia, M. Arshad, M. Chang, Z. Ahmad, Porous 933 
Inorganic Drug Delivery Systems—a Review, AAPS PharmSciTech. 18 (2017) 1507-934 
1525. 935 
[30] R.J. Ahern, A.M. Crean, K.B. Ryan, The influence of supercritical carbon dioxide 936 
(SC-CO2) processing conditions on drug loading and physicochemical properties, Int. 937 
J. Pharm. 439 (2012) 92-99. 938 
[31] J. Lu, M. Liong, J.I. Zink, F. Tamanoi, Mesoporous silica nanoparticles as a 939 
delivery system for hydrophobic anticancer drugs, Small. 3 (2007) 1341-1346. 940 
[32] J. Lu, M. Liong, S. Sherman, T. Xia, M. Kovochich, A.E. Nel, J.I. Zink, F. 941 
Tamanoi, Mesoporous silica nanoparticles for cancer therapy: energy-dependent 942 
 41 
 
cellular uptake and delivery of paclitaxel to cancer cells, Nanobiotechnology. 3 (2007) 943 
89-95. 944 
[33] L.J. Waters, T. Hussain, G. Parkes, J.P. Hanrahan, J.M. Tobin, Inclusion of 945 
fenofibrate in a series of mesoporous silicas using microwave irradiation, Eur J Pharm 946 
Biopharm. 85 (2013) 936-941. 947 
[34] M. Zamani, M.P. Prabhakaran, S. Ramakrishna, Advances in drug delivery via 948 
electrospun and electrosprayed nanomaterials, Int J Nanomedicine. 8 (2013) 2997-949 
3017. 950 
[35] M. Rasekh, A. Smith, M. S Arshad, O. Gunduz, M Van der Merwe, S, G. Smith, 951 
Z. Ahmad, Electrohydrodynamic preparation of nanomedicines, Curr. Top. Med. 952 
Chem. 15 (2015) 2316-2327. 953 
[36] H. Lin, C. Tang, C. Lin, Detailed structural characterizations of sba‐15 and mcm‐954 
41 mesoporous silicas on a high‐resolution transmission electron microscope, J. Chin. 955 
Chem. Soc. 49 (2002) 981-988. 956 
[37] L. Giraldo, B. López, L. Pérez, S. Urrego, L. Sierra, M. Mesa, Mesoporous silica 957 
applications, Macromol. Symp. 258 (2007) 129-141. 958 
[38] D.N. Dhar, The Chemistry of Chalcones and Related Compounds, John Wiley & 959 
Sons, 1981. 960 
[39] S. Dessault, BIOVIA Materials Studio, Release 2017. San Diego (2017). 961 
[40] D. Zhao, J. Feng, Q. Huo, N. Melosh, G.H. Fredrickson, B.F. Chmelka, G.D. 962 
Stucky, Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 963 
angstrom pores, Science. 279 (1998) 548-552. 964 
[41] K. Dimos, P. Stathi, M.A. Karakassides, Y. Deligiannakis, Synthesis and 965 
characterization of hybrid MCM-41 materials for heavy metal adsorption, Microporous 966 
and Mesoporous Materials. 126 (2009) 65-71. 967 
 42 
 
[42] N. Miriyala, D. Ouyang, Y. Perrie, D. Lowry, D.J. Kirby, Activated carbon as a 968 
carrier for amorphous drug delivery: Effect of drug characteristics and carrier 969 
wettability, Eur. J. Pharm. Biopharm. 115 (2017) 197-205. 970 
[43] C. Karavasili, M. Spanakis, D. Papagiannopoulou, I.S. Vizirianakis, D.G. 971 
Fatouros, S. Koutsopoulos, Bioactive Self-Assembling Lipid-Like Peptides as 972 
Permeation Enhancers for Oral Drug Delivery, J. Pharm. Sci. 104 (2015) 2304-2311. 973 
[44] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: 974 
Application to proliferation and cytotoxicity assays, J. Immunol. Methods. 65 (1983) 975 
55-63. 976 
[45] C. Karavasili, E.P. Amanatiadou, E. Kontogiannidou, G.K. Eleftheriadis, N. 977 
Bouropoulos, E. Pavlidou, I. Kontopoulou, I.S. Vizirianakis, D.G. Fatouros, 978 
Comparison of different zeolite framework types as carriers for the oral delivery of the 979 
poorly soluble drug indomethacin, Int. J. Pharm. 528 (2017) 76-87. 980 
[46] D. Rath, S. Rana, K. Parida, Organic amine-functionalized silica-based 981 
mesoporous materials: an update of syntheses and catalytic applications, RSC 982 
Advances. 4 (2014) 57111-57124. 983 
[47] P. Mehta, A.A. Al-Kinani, R. Haj-Ahmad, M.S. Arshad, M. Chang, R.G. Alany, 984 
Z. Ahmad, Electrically atomised formulations of timolol maleate for direct and on-985 
demand ocular lens coatings, Eur. J. Pharm. Biopharm. 119 (2017) 170-184. 986 
[48] K.K. Qian, R.H. Bogner, Application of Mesoporous Silicon Dioxide and Silicate 987 
in Oral Amorphous Drug Delivery Systems, J. Pharm. Sci. 101 (2012) 444-463. 988 
[49] S. Kumar, M. Gradzielski, S. Mehta, The critical role of surfactants towards CdS 989 
nanoparticles: synthesis, stability, optical and PL emission properties, RSC Advances. 990 
3 (2013) 2662-2676. 991 
 43 
 
[50] S. Shen, W.K. Ng, L. Chia, J. Hu, R.B.H. Tan, Physical state and dissolution of 992 
ibuprofen formulated by co-spray drying with mesoporous silica: Effect of pore and 993 
particle size, Int. J. Pharm. 410 (2011) 188-195. 994 
[51] Y. Zhang, Z. Zhi, T. Jiang, J. Zhang, Z. Wang, S. Wang, Spherical mesoporous 995 
silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan, 996 
J. Control. Release. 145 (2010) 257-263. 997 
[52] C.F. Fan, T. Caǧin, Wetting of crystalline polymer surfaces: A molecular dynamics 998 
simulation, J. Chem. Phys. 103 (1995) 9053-9061. 999 
[53] C.S. Thompson, R.A. Fleming, M. Zou, Transparent self-cleaning and antifogging 1000 
silica nanoparticle films, Sol. Energy Mater Sol. Cells. 115 (2013) 108-113. 1001 
[54] G. Maria, D. Berger, S. Nastase, I. Luta, Kinetic studies on the irinotecan release 1002 
based on structural properties of functionalized mesoporous-silica supports, 1003 
Microporous and Mesoporous Materials. 149 (2012) 25-35. 1004 
[55] J. Andersson, J. Rosenholm, S. Areva, M. Lindén, Influences of material 1005 
characteristics on ibuprofen drug loading and release profiles from ordered micro-and 1006 
mesoporous silica matrices, Chem. Mater. 16 (2004) 4160-4167. 1007 
[56] A.L. Doadrio, E.M.B. Sousa, J.C. Doadrio, J. Pérez Pariente, I. Izquierdo-Barba, 1008 
M. Vallet-Regı́, Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug 1009 
delivery, J. Controlled Release. 97 (2004) 125-132. 1010 
[57] J. Andersson, S. Areva, B. Spliethoff, M. Lindén, Sol–gel synthesis of a 1011 
multifunctional, hierarchically porous silica/apatite composite, Biomaterials. 26 (2005) 1012 
6827-6835. 1013 
[58] M. Ghasemnejad, E. Ahmadi, Z. Mohamadnia, A. Doustgani, S. Hashemikia, 1014 
Functionalized silica nanoparticles as a carrier for Betamethasone Sodium Phosphate: 1015 
 44 
 
Drug release study and statistical optimization of drug loading by response surface 1016 
method, Mater Sci Eng C. 56 (2015) 223-232. 1017 
[59] P. Nadrah, U. Maver, A. Jemec, T. Tišler, M. Bele, G. Dražić, M. Benčina, A. 1018 
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 FIGURE LEGENDS 1091 
Figure 1. Snapshots showing the location of the drug molecule in A. BEA and B. MCM 1092 
framework every 40ps during the simulation run. C. Root mean squared displacement 1093 
for KAZ3 in BEA and MCM-41. 1094 
 1095 
Figure 2. Jetting images i) micro-dripping ii) unstable jetting iii) stable cone jet iv) 1096 
stable multi-jet and jetting maps of A. SBA-15 in acetone B. SBA-15 in ethanol C. 1097 
MCM-41 in acetone D. MCM-41 in ethanol E. FS in acetone and  F. FS in ethanol. 1098 
 1099 
Figure 3. Scanning electron microscope images of A. and B. SBA-15 at 5 kX and 40 1100 
kX magnification, respectively. C. and D. SBA-Eth-SIM at 5 kX and 40 kX 1101 
magnification, respectively. E. and F. SBA-Eth-SP at 5 kX and 40 kX magnification, 1102 
respectively. SBA: SBA-15, Eth: Ethanol, SIM: solvent impregnation method and SP:  1103 
electrospraying method. 1104 
 1105 
Figure 4. XRD patterns A., B., C. of pristine silica materials and the drug loaded 1106 
formulations. D., E., F. DSC thermograms of SBA-15, MCM-41 and fumed silica-1107 
based formulations, SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, 1108 
AC: acetone, SIM: solvent impregnation method and SP:  electrospraying method. 1109 
 1110 
Figure 5. Plots of θο values versus time for A. SBA-15, B. MCM-41 and C. FS before 1111 
and after drug loading and D. digital images captured at different time intervals. SBA: 1112 
SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: solvent 1113 
impregnation method and SP:  electrospraying method. 1114 
 1115 
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Figure 6.  In vitro release profiles of pure KAZ3 and KAZ3 loaded silica particles A. 1116 
SBA-15, B. MCM-41 and C. FS using different solvents and loading methods (n=3). 1117 
SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: Ethanol, AC: acetone, SIM: 1118 
solvent impregnation method and SP:  electrospraying method. 1119 
 1120 
Figure 7. Ex vivo permeation profiles of plain drug and drug loaded in A. SBA-15, B. 1121 
MCM-41 and C. FS particles using the non-everted sac method in Krebs-Ringer 1122 
solution at 37 oC (n=3-5). SBA: SBA-15, MCM: MCM-41, FS: fumed silica, Eth: 1123 
Ethanol, AC: acetone, SIM: solvent impregnation method and SP:  electrospraying 1124 
method. 1125 
 1126 
Figure 8. A. Assessment of cell viability of Caco-2 cells exposed to KAZ3 (n=3). 1127 
The cellular viability of Caco-2 cell cultures without treatment (negative control), after 1128 
treatment with 1 % Triton X-100 (positive control) and after incubation with 0.1 mg/mL 1129 
and 1 mg/mL of KAZ3-loaded MCM-41, SBA-15 and FS materials, for B. 4 h, C. 24 h 1130 
and D. 48h was assessed by MTT assay (n=3). Eth: Ethanol, AC: acetone, SIM: solvent 1131 
impregnation method and SP:  electrospraying method. 1132 
 1133 
 1134 
 1135 
 1136 
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Table 1. Quantification of KAZ3 encapsulation efficiency (EE %) of the different formulations calculated by UV spectrophotometry and TGA. 1140 
1141 
Formulation 
 
MS type 
Loading 
Method 
Solvent EE (%)-UV 
 
EE (%)-TGA 
 
Silica wt. loss 
(%) 
(100 ◦C-800 ◦C ) 
 
Formulation wt. 
loss (%) 
(100 ◦C-800 ◦C) 
KAZ3 
content (%) 
EE (%) 
SBA-AC-SIM SBA-15 
Solvent 
impregnation 
Acetone 35.65 ± 3.25 8.23 25.7 17.47 69.88 
SBA-Eth-SIM SBA-15 
Solvent 
impregnation 
Ethanol 18.29 ± 0.86 8.23 24.29 16.06 64.25 
SBA-AC-SP SBA-15 EHDA Acetone 114.53 ± 5.25 8.23 41.29 33.06 132.26 
SBA-Eth-SP SBA-15 EHDA Ethanol 91.79 ± 0.42 8.23 34.75 26.52 106.10 
MCM-AC-SIM MCM-41 
Solvent 
impregnation 
Acetone 28.53 ± 0.73 14.8 29.33 14.53 58.13 
MCM-Eth-SIM MCM-41 
Solvent 
impregnation 
Ethanol 15.28 ± 10.28 14.8 29.91 15.11 60.45 
MCM-AC-SP MCM-41 EHDA Acetone 105.89 ± 5.05 14.8 41.15 26.35 105.41 
MCM-Eth-SP MCM-41 EHDA Ethanol 90.58 ± 0.72 14.8 32.3 17.50 70.0 
FS-AC-SIM Fumed silica 
Solvent 
impregnation 
Acetone 13.14 ± 2.95 8.16 27.34 19.18 76.72 
FS-Eth-SIM 
 
Fumed silica 
Solvent 
impregnation 
Ethanol 9.48 ± 0.38 8.16 29.24 21.24 84.98 
FS-AC-SP Fumed silica EHDA Acetone 115.18 ± 7.68 8.16 36.72 28.72 114.89 
FS-Eth-SP Fumed silica EHDA Ethanol 65.35 ± 0.37 8.16 29.42 21.42 85.71 
 50 
 
Table 2. Apparent permeability (Papp) and steady state flux (Jss) values of KAZ3 from 1142 
different formulations using the non-everted intestinal sac method (n=3-5).  1143 
Sample Jss (ng/min/cm2) Papp·10-7 (cm/s) Enhancement 
Ratio 
KAZ3 suspension 0.22 ± 0.02 8.88 ± 0.8 1 
SBA-Eth-SIM 0.21 ± 0.07 8.32 ± 2.8 0.9 
SBA-Eth-SP 0.63 ± 0.03 25.30 ± 1.2 2.8 
MCM-Eth-SIM 0.09 ± 0.01 3.60 ± 0.4 0.4 
MCM-Eth-SP 2.10 ± 0.02 84.0 ± 0.8 9.45 
FS-Eth-SIM 0.31 ± 0.01 12.5 ± 0.40 1.4 
FS-Eth-SP 0.83 ± 0.01 33.2 ± 0.39 3.7 
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FIGURE 7 1297 
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